Online inquiry

IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6921MR)

This product GTTS-WQ6921MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Alkaline phosphatase substitute gene. The antibody can be applied in Hypophosphatasia (HPP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000478.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 249
UniProt ID P05186
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6921MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4273MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ2545MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ3502MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ3030MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ14628MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ3584MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ6210MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ7514MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC-1102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW